Larimar initiated with bullish view at Oppenheimer on lead drug

seekingalpha10-16

Pgiam/iStock via Getty ImagesShares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2475914123?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750","is_english":true,"pubTime":"2024-10-16 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475914123","market":"fut","top_or_hot":-1,"title":"Larimar initiated with bullish view at Oppenheimer on lead drug","media":"seekingalpha","content":"<div>\n<p>Pgiam/iStock via Getty ImagesShares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead...</p>\n\n<a href=\"https://seekingalpha.com/news/4165258-larimar-stock-gets-bullish-view-at-oppenheimer\">Source Link</a>\n\n</div>\n","source":"seekingalpha_trending_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Larimar initiated with bullish view at Oppenheimer on lead drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLarimar initiated with bullish view at Oppenheimer on lead drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-16 23:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4165258-larimar-stock-gets-bullish-view-at-oppenheimer><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pgiam/iStock via Getty ImagesShares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead...</p>\n\n<a href=\"https://seekingalpha.com/news/4165258-larimar-stock-gets-bullish-view-at-oppenheimer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://seekingalpha.com/news/4165258-larimar-stock-gets-bullish-view-at-oppenheimer","article_id":"2475914123","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg?io=getty-c-w750"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475914123","pubTimestamp":1729091214,"sourceInfo":{"source_id":"seekingalpha_trending_news","name":"Seeking Alpha Trending News"},"weMediaInfo":null,"summary":"Pgiam/iStock via Getty ImagesShares of Larimar Therapeutics  gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead asset, nomlabofusp, targeted at a neurodegenerative disease called Friedreich's ataxia . Oppenheimer analyst Andreas Argyrides argued that","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","QLD":"纳指两倍做多ETF","BK4130":"人力资源与就业服务","FA":"First Advantage Corp.","OPY":"奥本海默控股","BK4535":"淡马锡持仓","TQQQ":"纳指三倍做多ETF","PSQ":"纳指反向ETF","BK4568":"美国抗疫概念","BK4588":"碎股","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4127":"投资银行业与经纪业","QID":"纳指两倍做空ETF","BK4539":"次新股","BNTX":"BioNTech SE",".IXIC":"NASDAQ Composite","SQQQ":"纳指三倍做空ETF","LRMR":"Larimar Therapeutics, Inc."},"translate_title":"拉里马尔(Larimar)在奥本海默(Oppenheimer)对先导药物持看涨观点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPY":1,"FA":1,"LRMR":0.9,".IXIC":0.7,"BNTX":0.7,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"Pgiam/iStock via Getty ImagesShares of Larimar Therapeutics (NASDAQ:LRMR) gained on Wednesday after Oppenheimer launched the company with an Outperform recommendation, citing the potential of its lead asset, nomlabofusp, targeted at a neurodegenerative disease called Friedreich's ataxia (FA). Oppenheimer analyst Andreas Argyrides argued that","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2475914123"}